Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCATCo Regulatory News (CAT)

  • This share is currently suspended. It was suspended at a price of 37.50
  • There is currently no data for CAT

Portfolio Update

7 Dec 2018 07:00

RNS Number : 7509J
CATCo Reinsurance Opps Fund Ltd
07 December 2018
 

FOR IMMEDIATE RELEASE

 

7 December 2018

CATCo Reinsurance Opportunities Fund Ltd. (the "Company")

Portfolio Update

 

 

To: SFS, London Stock Exchange and Bermuda Stock Exchange

 

Markel CATCo Investment Management Ltd., as Investment Manager of the Company (the "Manager"), announces its intention to increase the specific loss reserves held by the Company in relation to the Ordinary Shares for the 2017 loss events as indicated in the stock exchange announcement dated 22 November 2018.

 

The impact of the increase is estimated to be approximately 27.7 per cent of the 31 October 2018 Ordinary Share Net Asset Value ("NAV") and will be accounted for within the 30 November 2018 NAV. On a normalised basis, this represents approximately a 15.7 per cent deterioration in the Ordinary Share 2017 annual performance and is equivalent to a 2017 NAV return on the Ordinary Shares of approximately -57.1% per cent (down from the -41.4 per cent reported at year-end).

 

Following the 2017 Hurricanes Harvey, Irma, Maria (HIM) and the California Wildfires, the Manager has continued to monitor the ongoing uncertainty related to these loss events. As has been communicated previously, industry loss estimates have continued to deteriorate beyond reasonable expectations since the time of the last reserve provision made in April 2018. Since this time, the industry loss estimates on major 2017 loss events have increased by more than 12% as of December 2018.

 

In addition, based on an assessment of updated cedant loss data as of Q3 2018, further reserve strengthening is required. This expectation aligns not only with the increases of industry loss estimate trends, but also with the numerous reports of insurers, reinsurers, and ILS constituents who have continued to report ongoing loss deterioration throughout Q3 2018. As such, the Manager will strengthen reserves to be aligned with the observed wider market increases. Some level of uncertainty will remain until industry loss estimates cease to exhibit further growth.

 

Further, the Manager is continuing to assess the potential impacts to the portfolio related to the 2018 California wildfires. A material impact is expected to be recorded in the 30 November 2018 NAV. An update will be made to shareholders as soon as the potential impact to the private insurance marketplace is known.

 

 

 

For further information:

Markel CATCo Investment Management Ltd.

 

Judith Wynne

General Counsel

Telephone: +1 441 493 9005

Email: judith.wynne@markelcatco.com

 

Mark Way

Chief of Investor Marketing

Telephone: +1 441 493 9001

Email: mark.way@markelcatco.com

Numis Securities Limited

 

David Benda / Hugh Jonathan

Telephone: +44 (0) 20 7260 1000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
PFUGGBDDDUGBGIR
Date   Source Headline
13th Jun 20064:50 pmRNSRule 8.3- Cambridge Antibody
13th Jun 20063:54 pmRNSRule 2.10 Announcement
13th Jun 200612:18 pmRNSEPT Disclosure
13th Jun 200611:42 amRNSEPT Disclosure
13th Jun 200611:35 amRNSEPT Disclosure
13th Jun 200610:20 amRNSEPT Disclosure
12th Jun 20065:35 pmRNSRule 8.3 - Cambridge Antibody
12th Jun 200612:00 pmRNSEPT Disclosure
12th Jun 200611:34 amRNSEPT Disclosure
12th Jun 200611:14 amRNSRule 8.3- (CAT)
12th Jun 200610:08 amRNSEPT Disclosure
12th Jun 20067:00 amRNSRule 8.3- Cambridge Antibody
9th Jun 20061:30 pmRNSRule 8.3- (CAT)
9th Jun 200612:36 pmRNSEPT Disclosure
9th Jun 200611:56 amRNSEPT Disclosure
9th Jun 200611:54 amRNSEPT Disclosure
9th Jun 200611:38 amRNSRule 8.3-Cambridge Antibody
8th Jun 20064:19 pmRNSRule 2.10 Announcement
8th Jun 20062:21 pmRNSEPT Disclosure
8th Jun 20061:14 pmRNSRule 8.3- (CAT)
8th Jun 200610:49 amRNSEPT Disclosure
7th Jun 20065:01 pmRNSHolding(s) in Company
7th Jun 20064:55 pmRNSRule 8.3- Cambridge Anti Tech
7th Jun 200612:38 pmRNSRule 8.3- (CAT)
7th Jun 200612:08 pmRNSEPT Disclosure
7th Jun 200610:00 amRNSOffer for Cambridge Antibody
6th Jun 20064:01 pmRNSRule 8.3- Cambridge Antibody
6th Jun 20063:45 pmRNSRule 8.3- Cambridge Antibody
6th Jun 200612:43 pmRNSEPT Disclosure
5th Jun 20066:00 pmRNSEPT Disclosure
5th Jun 20061:10 pmRNSRule 8.3- (CAT)
5th Jun 200612:55 pmRNSEPT Disclosure
5th Jun 200611:24 amRNSEPT Disclosure
2nd Jun 20062:14 pmRNSEPT Disclosure
2nd Jun 20061:19 pmRNSRule 8.3- (CAT)
2nd Jun 200612:27 pmRNSEPT Disclosure
2nd Jun 200612:22 pmRNSEPT Disclosure
2nd Jun 20067:00 amRNSRule 8.3- Cambridge Antibody
1st Jun 20064:22 pmRNSRule 8.3- Cambridge Antibody
1st Jun 20063:21 pmRNSHolding(s) in Company
1st Jun 200612:25 pmRNSEPT Disclosure
1st Jun 200611:10 amRNSEPT Disclosure
31st May 20063:13 pmRNSRule 8.3- (CAT)
31st May 20063:00 pmRNSMerger Update
31st May 20061:04 pmRNSRule 8.3- Cambridge Antibody
31st May 200611:43 amRNSEPT Disclosure
31st May 200611:27 amRNSEPT Disclosure
31st May 200611:25 amRNSEPT Disclosure
30th May 20063:25 pmRNSRule 8.3- (CAT)
30th May 20063:16 pmRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.